Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7779]

FDA approves use of ponatinib for the treatment chronic myeloid leukaemia

FDA approves use of ponatinib for the treatment chronic myeloid leukaemia

Hard-to-treat Myc-driven cancers may be susceptible to drug already used in clinic

Hard-to-treat Myc-driven cancers may be susceptible to drug already used in clinic

New screening approach identified potential drug combinations for difficult-to-treat forms of melanoma

New screening approach identified potential drug combinations for difficult-to-treat forms of melanoma

'Significant' new cancer drug resistance mechanism identified

'Significant' new cancer drug resistance mechanism identified

Adding bevacizumab to platimum drugs in adjuvant treatment for colorectal cancer does not increase survival

Adding bevacizumab to platimum drugs in adjuvant treatment for colorectal cancer does not increase survival

FDA approves use of abiraterone acetate for metastatic castration-resistant prostate cancer

FDA approves use of abiraterone acetate for metastatic castration-resistant prostate cancer

Positive early results in clinical trial for DNA vaccine

Positive early results in clinical trial for DNA vaccine

ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

ASH 2012: Engineered immune cells produce complete response in child with an aggressive paediatric leukaemia

ASH 2012: Engineered immune cells produce complete response in child with an aggressive paediatric leukaemia

ASH 2012: First curative treatment for acute promyelocytic leukaemia that does not include chemotherapy

ASH 2012: First curative treatment for acute promyelocytic leukaemia that does not include chemotherapy

More from ecancer